Drugs / FXS5626
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07695779 | Aug → Sep 2026 overdue | — | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory Fosun Pharma’s Innovative Drug FXS5626 Approved for Clinical Trials in Non-Segmental Vitiligo fosunpharma.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma’s Innovative Drug FXS5626 Approved for Clinical Trials in Non-Segmental Vitiligo fosunpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXS5626 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07695779 ↗ |
| Route | Oral | “single dose, oral” NCT07695779 ↗ |